) to outperform from neutral, citing the company's plans to reduce and relocate beds at its Miami Facility.
Analyst Eric Coldwell says that while the impact of this news and damage to the company's reputation following a recent article is impossible to estimate, its valuation is attractive. He believes reduced estimates and price target more than offset the increased risk. He recommends the purchase of the stock for high risk investors. He cut his $27 target to $22, however.